« Return to News | Clinical Intelligence

Isis Pharmaceuticals reports phase I study results

Tuesday, March 8, 2011 10:39 AM

Isis Pharmaceuticals announced the results from a phase I clinical trial in which ISIS-CRPRx produced statistical reductions in C-reactive protein (CRP) in the cohort with elevated CRP.  ISIS-CRPRx was well tolerated at doses up to 600 mg/week.  Isis plans to evaluate ISIS-CRPRx in phase II studies in indications that could provide early proof-of-concept in diseases with elevated CRP.  Isis plans to initially evaluate ISIS-CRPRx in multiple myeloma and rheumatoid arthritis, and then move to cardiovascular and other diseases.

The phase I study was a blinded, randomized, placebo-controlled, dose-escalation study designed to assess the safety and pharmacokinetic profile of ISIS-CRPRx as well as to assess the initial effects of the drug on baseline CRP levels.  ISIS-CRPRx was evaluated in single and multiple doses ranging from 50 mg per week to 600 mg per week in 80 healthy volunteers.  In all but one cohort, Isis enrolled subjects who had normal CRP levels.  In the 600 mg per week multi-dose cohort, Isis enrolled eight subjects with elevated levels of CRP.  The subjects in this cohort had an average CRP level at baseline of approximately 3.0 mg/L. 

After only three weeks of dosing, the six subjects who received ISIS-CRPRx had an average CRP level of 0.76 mg/L, which is within the normal range of CRP and represents an average reduction of greater than 70% compared to placebo.  Subjects receiving placebo remained elevated above 3.0 mg/L.  In all subjects receiving the drug, it was well tolerated with no serious adverse events.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.